Abstract: A series of eighteen novel esters of salicylanilides with benzenesulfonic acid were designed, synthesized and characterized by IR, 1 H-NMR and 13 C-NMR. They were evaluated in vitro as potential antimycobacterial agents towards Mycobacterium tuberculosis, Mycobacterium avium and two strains of Mycobacterium kansasii. In general, the minimum inhibitory concentrations range from 1 to 500 µmol/L. The most active compound against M. tuberculosis was 4-chloro-2-(4-(trifluoromethyl)phenylcarbamoyl)-phenyl benzenesulfonate, with MIC of 1 µmol/L and towards M. kansasii its isomer 5-chloro-2-(4-(trifluoromethyl)phenylcarbamoyl)phenyl benzenesulfonate (MIC of 2-4 µmol/L). M. avium was the less susceptible strain. However, generally, salicylanilide benzenesulfonates did not surpass the activity of other salicylanilide esters with carboxylic acids.
Introduction
Tuberculosis (TB) is still a global health problem. According to the WHO, in 2010 about 8.8 million people were infected by TB, including 1.1 million cases among HIV-infected patients. In the same year, 1.4 million died due to TB [1] .
OPEN ACCESS
Recently, the increasing emergence of drug-resistant tuberculosis, especially multidrug-resistant tuberculosis (MDR-TB) and most recently extensively drug-resistant tuberculosis (XDR-TB) is alarming. A multidrug-resistant Mycobacterium tuberculosis strain was identified and defined as resistant to at least the two most effective anti-TB drugs-Isoniazid (INH) and rifampicin (RIF)-but it may include additional resistance to more antituberculotics. XDR-TB was defined as a resistance to any fluoroquinolone and to at least one of the three injectable drugs (capreomycin, kanamycin, or amikacin) [2, 3] . In 2010, there was an estimated prevalence of 650,000 cases and about 150,000 MDR-TB deaths annually [1] . These problems and serious co-infection of TB with HIV present a serious challenge for the research to find a new type of drug or prodrug with an innovative mechanism of the action [2] .
Salicylanilides (2-hydroxy-N-phenylbenzamides) have been revealed to demonstrate a wide range of perspective biological activities and some of them are used in human or veterinarian medicine. Salicylanilides, e.g., modulate immune response and inflammatory processes [4, 5] , show analgesic efficacy [6] , influence on ion channels [7] and they express more molecular effects which may be useful in the development of anti-cancer drugs, e.g., references [8, 9] . Salicylanilides have been studied for their significant activity against various parasites like protozoa, mycobacteria, fungi, bacteria (especially Gram-positive) or viruses [10] . Antimicrobial salicylanilides probably act by multiple mechanisms of the action [11] , e.g., they disrupt membrane functions, inhibit some enzymes, block the incorporation of some nutrients [12] , they act as the uncoupling agents of mitochondrial oxidative phosphorylation due to their protonophoric activity dissipating the protonmotive force [13] ; from newer findings it is important that salicylanilides are able to inhibit the two-component regulatory systems which are involved in the maintenance of bacterial cell homeostasis and the expression of virulence factors [14] .
Salicylanilides contain a free hydroxyl (phenolic) group generally presumed to be necessary for the activity, although its temporary masking by the esterification may be advantageous. The blockade of polar hydrophilic group can result in improved physico-chemical properties and thus better bioavailability, membrane permeability, a high activity and/or a lower toxicity and an irritant potency. In general, salicylanilide esters exhibited a similar or a sharply better antimicrobial activity than parent salicylanilides [11, 15] .
Salicylanilide esters as potential prodrugs have exhibited generally the very good antimycobacterial activity from 0.125 μmol/L and including MDR-TB strains [11] . Salts of benzenesulfonic acid, called also besylates, have been used in medicine as pharmaceuticals, as well as tosylates and mesylates [16] .
In this study, we have chosen sulfonic acid instead of previously used carboxylic acids for the esterification (e.g., references [15, 17, 18] ).
Results and Discussion

Chemistry
Salicylanilide benzenesulfonates were synthesised by two step synthesis. Firstly, salicylanilides 1 were prepared by the procedure using microwave irradiation described previously by our group, e.g., references [19] (see Scheme 1). Then they were converted to esters 2 by benzenesulfonyl chloride in the presence of triethylamine (Et 3 N; see Scheme 2); the base and solvent were chosen according to e.g., references [20] . Esterification of salicylanilides with benzenesulfonic acid via N,N´-dicyclohexylcarbodiimide in N,N-dimethylformamide failed. Scheme 1. Synthesis of salicylanilides.
Scheme 2. Synthesis of salicylanilide benzenesulfonates. 
In Vitro Antimycobacterial Evaluation
All synthesized benzenesulfonates 2 were evaluated in vitro towards four mycobacterial strainsMycobacterium tuberculosis, Mycobacterium avium and two strains of M. kansasii after 14 and 21 days of incubation, for M. kansasii additionally after 7 days. The results are summarized in the Table 1 .
Except for compound 2q, for which it was not possible to determine minimal inhibition concentrations (MIC), all salicylanilide benzenesulfonates exhibited a significant in vitro activity against M. tuberculosis as the most sensitive strain at the concentration values up to 16 μmol/L. The most active derivatives were 4-chloro-2-(3,4-dichlorophenylcarbamoyl)phenyl benzenesulfonate (2e; 1/2 μmol/L) and 4-chloro-2-(4-(trifluoromethyl)phenylcarbamoyl)phenyl benzenesulfonate (2q; 1/1 μmol/L). 4-Chloro derivatives mostly showed lower MICs than their 5-chloro counterparts, in the case of 2i and 2j, 2k and 2l are both derivatives equally active. With respect to the aniline substitution pattern, the most suitable moieties are trifluoromethyl group and 3,4-dichloro substitution, whereas fluorine produced the weakest effect. With respect to the lipophilicity (calculated logP), there is no clear dependence, however this physico-chemical property seems to be one of the factors influencing the antimycobacterial activity. On the other side, the highest activity towards M. tuberculosis displayed the most lipophilic salicylanilide derivatives containing either CF 3 group (2o, 2q, 2r; ClogP 5.40) or 3,4-dichloroaniline fragment (2e; ClogP 5.60) and the highest MIC exhibited the least lipophilic fluorinated esters (ClogP 4.64), but strongly lipophilic 2p showed an undetectable activity. Salicylanilide esters of 3-or 4-bromoaniline (compounds 2g, 2h, 2i, 2j) with only a slightly lower calculated lipophilicity (ClogP 5.31) than trifluoromethylanilines displayed a lower average anti-mycobacterial activity than chloro derivatives (2a, 2b, 2c, 2d; ClogP 5.04). Additionally, the calculated lipophilicity could not explain the differences of MIC between corresponding isomers. MIC values of the two most active derivatives 2e and 2q are comparable with the standards-Fist-line oral antituberculosis drugs isoniazid and ethambutol (EMB). Seventeen derivatives exhibited a significantly higher in vitro activity than the second-line drug para-aminosalicylic acid (PAS), which also shares a salicylic fragment.
Atypical mycobacteria displayed a higher rate of resistance, particularly M. avium with MIC value range from 8 μmol/L (2d and 2j). MIC exceeded 500 μmol/L for two esters-2b and 2k. The favourable substituents of the aniline ring are 4-chlorine and bromine, especially when the position 5 of the salicylic ring is occupied. In contrast to M. tuberculosis, a trifluoromethyl moiety brings a minimal benefit in the comparison to each other except 3-fluorine, whose derivatives showed a higher MIC of ≥500 μmol/L. Eleven benzenesulfonates certainly surpassed the activity of INH, nine of PAS and two of EMB.
Both strains of M. kansasii expressed an intermediate sensitivity with no distinct differences between collection and clinically isolated types. MIC for 235/80 strain lies from 2 to ≥125 μmol/L and in the range of 4-500 μmol/L for the strain 6509/96. 5-Chloro-2-(4-(trifluoromethyl)phenylcarbamoyl)-phenyl benzenesulfonate (2r) is the most active molecule in the tested panel with MIC of 2-4 µmol/L, i.e., comparable to INH for both strains. Salicylanilide benzenesulfonates exhibited significantly higher in vitro activity towards M. kansasii 235/80 than INH, but not for 6509/96; PAS was not equally or more active than esters 2 against both strains, whereas no benzenesulfonate surpassed the MIC of EMB. Similarly to M. avium, the type of the salicylic ring substitution influences the activity ambiguously and the best MIC bring anilines having 4-Br or 4-Cl then 3,4-diCl substituents. The molecules with CF 3 group showed the lowest (2r), moderate (2o) or undetected (2p, 2q) MIC values. When concentrated on the position of each substituent on the aniline ring, 4-derivatives showed enhanced activity.
Salicylanilide benzenesulfonates displayed an obvious antimycobacterial activity in the range of 1-500 µmol/L with 2p being a partial exception. In comparison with the starting salicylanilides [21] , their benzenesulfonylation led to the derivatives with equal or increased MIC against atypical mycobacteria. Interestingly for M. tuberculosis, the modification of 5-chlorosalicylanilides (i.e., 4-chloro esters) resulted in a retained or an improved activity (e.g., four times for 2e), whereas benzenesulfonates derived from 4-chlorosalicylanilides exhibited mostly similar or lower antimycobacterial activity in vitro than parent salicylanilides. However, when compared to other esters of carboxylic acids, they can be considered as being only moderately potent in vitro. Salicylanilide esters with N-acetyl-L-phenylalanine [15] and carbamates [22] showed markedly lower MIC than benzenesulfonates, acetates [18] demonstrated a rather superior antimycobacterial effect. Esters with various N-benzyloxycarbonyl -amino acids [17] were more active against M. tuberculosis; the comparison of the MIC values towards M. kansasii appears being at similar level, however esters of some parent salicylanilides (modified in this study) as potential antimycobacterial agents were not published previously.
Experimental
General Methods
All used reagents and solvents were purchased from commercial sources (Sigma-Aldrich, Penta) and used without a further purification. Reactions were monitored by thin layer chromatography, plates were coated with 0.2 mm of silica gel 60 F254 (Merck) and were visualized by UV irradiation (254 nm). Melting points were determined on the Melting Point machine B-540 (Büchi) apparatus using open capillaries and they are uncorrected.
Infrared spectra (ATR) were recorded on FT-IR spectrometer Nicolet 6700 FT-IR in the range of 400-4,000 cm 
Synthesis of Salicylanilide Benzenesulfonates
An equivalent of appropriate salicylanilide (0.001 mol) was suspended with stirring in dichloromethane (DCM, 10 mL) and then triethylamine (1.5 of equivalents; 0.0015 mol) was added in one portion. The mixture was led to stir for 5 minutes to allow complete dissolution of the salicylanilide. Then benzenesulfonyl chloride (1.2 of equivalent; 0.0012 mol) was added and the mixture was stirred at the room temperature for two hours. The reaction was monitored using TLC and a toluene/methanol 9:1 mixture as eluent. After this time, the solution was evaporated till dryness, ethyl-acetate was added and the suspension was let stay at +4 °C for approximately 30 min. Then the insoluble part was removed by filtration, the filtrate was collected, partly evaporated and then added n-hexane to start crystallization. It was performed for 24 hours at +4 °C and the filtrates were filtered off to give esters. If necessary, they were recrystallized from boiling ethyl-acetate to afford white crystals. 41 (6H, m, H2′, H3′, H5′, H6′, H3′′, H5′′ 
4-Chloro-2-(3-chlorophenylcarbamoyl)phenyl benzenesulfonate (2a
5-Chloro-2-(3-chlorophenylcarbamoyl)phenyl benzenesulfonate (2b
4-Chloro-2-(4-chlorophenylcarbamoyl)phenyl benzenesulfonate (2c
2-(3-Bromophenylcarbamoyl)-4-chlorophenyl benzenesulfonate (2g
2-(3-Bromophenylcarbamoyl)-5-chlorophenyl benzenesulfonate (2h
5-Chloro-2-(3-fluorophenylcarbamoyl)phenyl benzenesulfonate (2l
4-Chloro-2-(4-fluorophenylcarbamoyl)phenyl benzenesulfonate (2m
4-Chloro-2-(3-(trifluoromethyl)phenylcarbamoyl)phenyl benzenesulfonate (2o
5-Chloro-2-(3-(trifluoromethyl)phenylcarbamoyl)phenyl benzenesulfonate (2p
4-Chloro-2-(4-(trifluoromethyl)phenylcarbamoyl)phenyl benzenesulfonate (2q
